title: Decoding and unlocking the BCL-2 dependency of cancer cells.
abstract: Cancer cells are subject to many apoptotic stimuli that would kill them were it not for compensatory prosurvival alterations. BCL-2-like (BCL-2L) proteins contribute to such aberrant behaviour by engaging a network of interactions that is potent at promoting survival but that is also fragile: inhibition of a restricted number of interactions may suffice to trigger cancer cell death. Currently available and novel compounds that inhibit these interactions could be efficient therapeutic agents if this phenotype of BCL-2L dependence was better understood at a molecular, cellular and systems level and if it could be diagnosed by relevant biomarkers.
authors.affiliation: Team 8 Cell survival and tumor escape in breast cancer, UMR 892 INSERM / 6299 CNRS / Université de Nantes, Institut de Recherche Thérapeutique de l'Université de Nantes, 8 quai Moncousu, BP 70721, 44007 Nantes Cedex, 1 France. philippe.juin@univ-nantes.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Juin
authors.forename: Olivier
authors.initials: O
authors.lastname: Geneste
authors.forename: Fabien
authors.initials: F
authors.lastname: Gautier
authors.forename: Stéphane
authors.initials: S
authors.lastname: Depil
authors.forename: Mario
authors.initials: M
authors.lastname: Campone
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2